We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

MR-Guided Focused Ultrasound Controls Prostate Cancer with Fewer Side Effects

By HospiMedica International staff writers
Posted on 16 Jun 2022
Print article
Image: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects (Photo courtesy of Pexels)
Image: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects (Photo courtesy of Pexels)

When the cancer is confined to the prostate gland, the main treatment options have traditionally included active surveillance (close monitoring), surgery, and radiation. But men who needed surgery or radiation often had persistent side effects, such as urinary and sexual problems, that could reduce quality of life. In recent years, a new treatment strategy known as focal therapy (partial gland ablation) has emerged for prostate cancer considered to be “intermediate risk” - mostly, small tumors confined to one area of the prostate. Now, a landmark clinical trial has demonstrated that an advanced focal therapy approach and less-invasive method known as high-intensity focused ultrasound (HIFU), guided by magnetic resonance imaging (MRI), works well for many patients.

Results from the clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) represent a major step toward having the new HIFU approach become part of widespread prostate cancer treatment. The phase 2 trial looked at a particular type of HIFU treatment, also called MR-guided focused ultrasound (MRgFUS), in men with intermediate-risk cancer. The novel approach effectively controlled the disease in patients and greatly reduced adverse side effects of treatment. This suggests many men with intermediate-risk prostate cancer can avoid surgery, chemotherapy, and radiation.

MRgFUS is an outpatient treatment that takes about two hours. Patients under anesthesia are placed in an MRI machine that covers the lower half of the body. After the machine takes an image of the prostate, the doctors outline the treatment area and deliver the focused ultrasound waves, guided by the MRI. The ultrasound waves come from different directions, intersecting to attack and kill the cancer by heating the cells to more than 158 °F (70 °C).

In the phase 2 clinical trial, 101 men received the novel MRgFUS treatment and then were biopsied six months and 24 months later. There was no intermediate- or higher-risk cancer left in the treated area for 88% of the patients. Based on this data, the FDA in December 2021 granted approval for the technology, called Exablate Prostate, to treat prostate tissue. The FDA also approved an investigator-initiated trial to compare MRgFUS focal therapy to active surveillance and demonstrate a clinical benefit for patients with prostate cancer. Using MRgFUS for intermediate-risk cancers has become possible due to two important developments over the past 15 years. First, there was an acceptance by experts of using active surveillance for low-grade tumors. The second advance was new imaging technology that enabled MRIs to be incorporated into ultrasound treatment.

“We believe this novel treatment strategy will improve the lives of many prostate cancer patients,” said MSK urologic cancer surgeon Behfar Ehdaie who led the phase 2 trial. “To draw a parallel with how breast cancer treatment changed 30 years ago, you could think of focal therapy as a ‘male lumpectomy.’ Instead of removing all the tissue in a breast or prostate, we have learned that it is safe and effective to treat specific areas and greatly reduce the burden on patients.”

“Advancements in prostate cancer over the past two decades have been headlined by successes that have benefited all patients, and now focal therapy provides another exciting area that can move the needle in prostate cancer management,” Dr. Ehdaie added.

Related Links:
MSK 


Print article
Radcal

Channels

AI

view channel
Image: ‘Hologram patients’ developed to help train doctors and nurses (Photo courtesy of University of Cambridge)

Life-Like Hologram Patients Train Doctors for Real-Time Decision Making in Emergencies

A medical training project using 'mixed reality' technology aims to make consistent, high-level and relevant clinical training more accessible across the world. University of Cambridge (Cambridge, UK)... Read more

Surgical Techniques

view channel
Image: The Senhance surgical system with digital laparoscopy (Photo courtesy of Asensus Surgical)

Digital Laparoscopic Platform Leverages Augmented Intelligence and Machine Learning

Challenges in laparoscopic surgery can impact cost, utilization, effectiveness, and outcomes of the procedure. For instance, the inability of the surgeon to control vision can create efficiency and safety... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more

Business

view channel
Image: Expanding the role of autonomous robots can mitigate the shortage of physicians (Photo courtesy of Pexels)

Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries

An aging population and accompanying retirements will cause a significant physician shortfall of 55,000 to 150,000 by 2030, creating a gap in the healthcare system. Expanding the role of autonomous robots... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.